Outset Medical, Inc. (NASDAQ:OM) CEO Leslie Trigg Sells 10,227 Shares

Outset Medical, Inc. (NASDAQ:OM) CEO Leslie Trigg sold 10,227 shares of the business’s stock in a transaction dated Tuesday, January 7th. The stock was sold at an average price of $1.29, for a total value of $13,192.83. Following the transaction, the chief executive officer now owns 894,624 shares in the company, valued at approximately $1,154,064.96. This represents a 1.13 % decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this link.

Leslie Trigg also recently made the following trade(s):

• On Friday, November 15th, Leslie Trigg sold 5,645 shares of Outset Medical stock. The shares were sold at an average price of $0.80, for a total value of $4,516.00.

Outset Medical Stock Performance

NASDAQ:OM opened at $1.10 on Wednesday. Outset Medical, Inc. has a 1-year low of $0.44 and a 1-year high of $5.67. The stock has a market cap of $57.80 million, a P/E ratio of -0.40 and a beta of 2.05. The company has a debt-to-equity ratio of 4.12, a current ratio of 6.49 and a quick ratio of 5.04. The firm has a 50-day moving average of $0.98 and a two-hundred day moving average of $1.50.

Institutional Inflows and Outflows

A number of institutional investors and hedge funds have recently bought and sold shares of OM. Los Angeles Capital Management LLC acquired a new position in Outset Medical during the 2nd quarter worth $731,000. Acadian Asset Management LLC lifted its position in shares of Outset Medical by 5.2% during the second quarter. Acadian Asset Management LLC now owns 819,563 shares of the company’s stock worth $3,154,000 after purchasing an additional 40,321 shares during the last quarter. Ground Swell Capital LLC acquired a new position in Outset Medical in the second quarter worth about $49,000. Massachusetts Financial Services Co. MA increased its holdings in Outset Medical by 118.5% in the second quarter. Massachusetts Financial Services Co. MA now owns 1,538,859 shares of the company’s stock valued at $5,925,000 after buying an additional 834,663 shares during the last quarter. Finally, Vanguard Personalized Indexing Management LLC acquired a new stake in Outset Medical during the second quarter valued at approximately $49,000.

Analyst Upgrades and Downgrades

Separately, Royal Bank of Canada reaffirmed a “sector perform” rating and issued a $3.00 price objective on shares of Outset Medical in a research report on Tuesday.

About Outset Medical

Outset Medical, Inc, a medical technology company, engages in the development of a hemodialysis system for hemodialysis in the United States. The company offers Tablo Hemodialysis System, a compact console with integrated water purification, on-demand dialysate production, and software and connectivity capabilities for dialysis care in acute and home settings; and manufactures, supports, and distributes for Tablo console, Tablo cartridge, and other consumables.